Tourmaline Competitors

Delisted . USA . 
Stock . Tourmaline Bio
TRMLDelisted Stock   47.98  0.00  0.00%   
Tourmaline Bio competes with Terns Pharmaceuticals, Precigen, Immatics, Oric Pharmaceuticals, and Enliven Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Tourmaline Bio competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Tourmaline Bio to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Tourmaline Bio vs Syndax Pharmaceuticals Correlation

Almost no diversification

The correlation between Tourmaline Bio and SNDX is 0.9 (i.e., Almost no diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Tourmaline Bio and SNDX in the same portfolio, assuming nothing else is changed.

Moving together with Tourmaline Stock

  0.91WMT Walmart Common Stock Sell-off TrendPairCorr
  0.88SAR Saratoga Investment CorpPairCorr

Moving against Tourmaline Stock

  0.74HNHPF Hon Hai PrecisionPairCorr
  0.73MSFT Microsoft Earnings Call This WeekPairCorr
  0.68JD JD Inc AdrPairCorr
  0.61HPQ HP IncPairCorr
  0.58T ATT Inc Earnings Call This WeekPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
47.9847.9847.98
Details
Intrinsic
Valuation
LowRealHigh
35.0335.0352.78
Details
Naive
Forecast
LowNextHigh
51.3451.3451.34
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
47.8247.9248.01
Details

Tourmaline Bio Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Tourmaline Bio and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Tourmaline and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Tourmaline Bio does not affect the price movement of the other competitor.

High positive correlations

SNDX
+ 0.93
TERN
WVE
+ 0.84
TERN
SNDX
+ 0.74
RLAY
SNDX
+ 0.73
DNTH
SNDX
+ 0.73
WVE
WVE
+ 0.71
RLAY
  

High negative correlations

ORIC
- 0.82
TERN
WVE
- 0.79
ORIC
SNDX
- 0.78
ORIC
RLAY
- 0.75
ORIC
WVE
- 0.42
AMLX
AMLX
- 0.37
TERN

Risk-Adjusted Indicators

There is a big difference between Tourmaline Stock performing well and Tourmaline Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Tourmaline Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TERN  5.79  2.70  0.68 (1.22) 2.66 
(7.65)
 13.30 
(6.06)
 76.18 
PGEN  3.78  0.39  0.07  1.30  4.66 
(4.10)
 8.52 
(7.08)
 38.64 
IMTX  2.96 (0.11) 0.00 (0.11) 0.00 
 0.00 
 7.31 
(6.47)
 30.34 
ORIC  2.76 (0.06)(0.02) 0.01  3.06 
(3.39)
 6.63 
(4.36)
 15.34 
ELVN  4.12  0.34  0.08  0.25  4.52 
(4.56)
 6.28 
(7.81)
 54.02 
AMLX  2.73  0.14  0.01 (0.17) 2.88 
(3.22)
 8.11 
(4.94)
 19.81 
RLAY  2.88  0.08  0.02  0.16  3.22 
(3.21)
 5.60 
(5.45)
 27.25 
DNTH  2.73  0.67  0.20 (1.12) 2.42 
(3.39)
 8.00 
(4.51)
 22.10 
WVE  6.41  1.99  0.34 (0.67) 4.26 
(8.49)
 8.92 
(8.08)
 164.47 
SNDX  2.77  0.44  0.15  2.06  2.36 
(3.72)
 8.70 
(3.59)
 18.37 

Tourmaline Bio Competitive Analysis

The better you understand Tourmaline Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Tourmaline Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Tourmaline Bio's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TRML TERN PGEN IMTX ORIC ELVN AMLX RLAY DNTH WVE
 0.00 
 47.98 
Tourmaline
 0.35 
 34.45 
Terns
 0.21 
 4.75 
Precigen
 1.82 
 9.73 
Immatics
 2.17 
 12.25 
Oric
 0.35 
 25.87 
Enliven
 4.76 
 15.01 
Amylyx
 2.15 
 7.59 
Relay
 2.22 
 51.17 
Dianthus
 1.63 
 13.25 
Wave
Market Volatility
(90 Days Market Risk)
Very steady
Somewhat reliable
Relatively risky
Somewhat reliable
Not too volatile
Somewhat reliable
Somewhat reliable
Slightly risky
Very steady
Unstable
Market Performance
(90 Days Performance)
Weakest
Solid
Mild
Weakest
Weakest
Mild
Soft
Weak
Good
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Fair
Small
Low
High
Low
Fair
Low
Small
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
N/A
23.59
5.51
2.95
18.72
N/A
7.96
15.22
N/A
2.5
Net Asset
309 M
363.93 M
145.27 M
696.15 M
274.14 M
325.76 M
193.63 M
871.3 M
374.01 M
352.21 M
Profit Margin
N/A
N/A
N/A
-1.42
N/A
N/A
N/A
N/A
N/A
-1.12
EBITDA
(89.73 M)
(100.97 M)
(123.5 M)
34.46 M
(126.74 M)
(104.24 M)
(290.98 M)
(380.21 M)
(101.45 M)
(101.74 M)
Current Valuation
993.63 M
3.44 B
1.66 B
841.44 M
883.86 M
1.05 B
1.39 B
724.68 M
1.84 B
2.33 B
Price To Book
4.75
13.14
40.23
2.71
2.87
3.21
5.21
2.12
4.11
20.09
Operating Margin
N/A
N/A
-32.54
-10.53
N/A
N/A
291.04
-38.87
-101.74
-7.41
Retained Earnings
(135.26 M)
(421.48 M)
(2.09 B)
(589.54 M)
(562.77 M)
(243.47 M)
(606.69 M)
(1.74 B)
(174.39 M)
(1.12 B)
Current Asset
N/A
N/A
285.72 M
N/A
N/A
N/A
N/A
N/A
N/A
161.38 M
Beta
1.58
-0.28
1.16
1.36
1.36
1.2
-0.31
1.56
1.26
-1.82
Number Of Employees
76
59
143
645
106
65
123
188
78
287
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
N/A
50.03
N/A
N/A
N/A
Shares Outstanding
25.69 M
108.77 M
352.91 M
134.06 M
97.39 M
59.35 M
109.82 M
173.32 M
42.88 M
185.76 M
Cash Flow From Operations
(77.26 M)
(70.02 M)
(68.17 M)
(158.03 M)
(112.66 M)
(73.19 M)
(167.65 M)
(249.11 M)
(78.18 M)
(151.03 M)
Total Debt
244 K
1.35 M
5.5 M
16.2 M
3.18 M
15.91 M
1.98 M
48.5 M
1.49 M
25.4 M
Return On Equity
-0.3
-0.29
-6.68
-0.3
-0.4
-0.25
-0.57
-0.41
-0.29
-0.87
Return On Asset
-0.21
-0.2
-0.67
-0.16
-0.25
-0.18
-0.39
-0.25
-0.19
-0.28
Number Of Shares Shorted
808.96 K
15.45 M
35.58 M
5.46 M
21.47 M
8.31 M
13.64 M
22.23 M
6.14 M
14.69 M
Book Value Per Share
10.09
3.25
-0.12
4.05
4.18
8.03
3.03
3.52
12.75
0.78
Current Liabilities
N/A
N/A
66.91 M
N/A
N/A
N/A
N/A
N/A
N/A
3.82 M
Total Asset
309 M
363.93 M
145.27 M
696.15 M
274.14 M
325.76 M
193.63 M
871.3 M
374.01 M
352.21 M
Short Ratio
1.12
3.41
7.04
10.49
14.98
10.74
9.22
10.21
9.48
1.16
Target Price
48.0
58.13
8.25
19.13
21.0
41.38
20.22
14.6
65.09
31.93
Debt To Equity
N/A
0.01
3.73
0.13
0.054
N/A
0.036
0.06
N/A
1.02
Shares Owned By Institutions
89.12
82.63
63.48
77.11
93.29
91.77
92.44
97.98
96.7
79.46
Market Capitalization
1.23 B
3.73 B
1.36 B
1.33 B
1.17 B
1.53 B
1.73 B
1.29 B
2.24 B
2.5 B
Price To Earning
N/A
N/A
-2.06
44.61
N/A
N/A
N/A
N/A
N/A
-6.5
Price To Earnings To Growth
N/A
N/A
-1.52
3.0
N/A
N/A
-0.15
0.07
N/A
N/A
Price To Sales
N/A
302.64
266.95
15.68
N/A
N/A
4.44
154.13
728.95
22.91
Net Income
(73.21 M)
(88.85 M)
(126.23 M)
15.22 M
(127.85 M)
(89.02 M)
(301.74 M)
(337.71 M)
(84.97 M)
(97.01 M)
Earnings Per Share
-3.44
-1.02
-0.41
-1.09
-1.71
-1.81
-1.79
-1.72
-3.5
-0.65
Shares Owned By Insiders
14.62
0.59
13.73
18.8
6.71
8.23
7.56
1.32
3.3
13.73
Revenue
N/A
N/A
3.92 M
155.84 M
N/A
N/A
87.37 M
10.01 M
6.24 M
108.3 M
Working Capital
259.93 M
346.46 M
80.9 M
561.57 M
237.4 M
302.21 M
161.03 M
758.48 M
262.45 M
209.44 M
Cash And Equivalents
N/A
139.81 M
115.3 M
324.38 M
227.06 M
N/A
206.68 M
1.05 B
N/A
148.16 M
Cash Per Share
N/A
5.51
0.55
5.0
5.74
N/A
3.53
8.72
N/A
1.71
Gross Profit
N/A
1000 K
(52.67 M)
(91.28 M)
N/A
N/A
(92.75 M)
(259.24 M)
3.08 M
(65.38 M)
Day Typical Price
47.98
34.35
4.64
9.66
12.01
25.84
15.18
7.6
50.96
13.32
Accumulation Distribution
N/A
57096.7
302147.0
14014.34
0.0596
20654.6
69079.65
183267.0
16820.4
56236.39
Market Facilitation Index
N/A
0.0
N/A
0.0
0.73
0.0
N/A
N/A
0.0
N/A
Daily Balance Of Power
0.0
0.0851
(0.02)
(0.36)
0.3562
0.1169
(1.07)
0.3404
(0.68)
(0.48)
Period Momentum Indicator
N/A
0.12
(0.01)
(0.18)
0.26
0.09
(0.75)
0.16
(1.16)
(0.22)
Rate Of Daily Change
1.0
1.0
1.0
0.98
1.02
1.0
0.95
1.02
0.98
0.98
Day Median Price
47.98
34.31
4.59
9.62
11.89
25.83
15.27
7.61
50.85
13.35
Price Action Indicator
N/A
0.21
0.16
0.02
0.5
0.09
(0.63)
0.065
(0.26)
(0.21)
Relative Strength Index
90.44
55.53
56.79
47.64
61.05
60.14
56.85
47.73
66.03
48.88
Coefficient Of Variation
571.68
423.15
1271.43
(8,149)
20174.57
1606.25
3533.82
2929.85
627.18
1039.66
Mean Deviation
2.68
5.79
3.78
2.96
2.76
4.12
2.73
2.88
2.73
6.41
Jensen Alpha
1.17
2.7
0.3939
(0.11)
(0.06)
0.3396
0.1412
0.0761
0.6749
1.99
Total Risk Alpha
0.5982
1.54
(0.09)
(0.48)
(0.34)
(0.25)
(0.27)
(0.26)
0.2579
0.0434
Sortino Ratio
0.6745
0.6782
0.0714
N/A
(0.02)
0.0808
0.0112
0.0184
0.1961
0.3355
Downside Variance
3.3
13.43
23.66
N/A
10.5
24.3
8.64
11.8
8.39
26.84
Standard Deviation
7.46
10.85
5.41
4.49
3.71
7.65
3.93
4.15
4.05
18.88
Kurtosis
52.81
23.89
6.44
4.29
1.45
27.67
3.94
8.22
3.7
56.27
Potential Upside
6.53
13.3
8.52
7.31
6.63
6.28
8.11
5.6
8.0
8.92
Treynor Ratio
0.7255
(1.22)
1.3
(0.11)
0.008
0.2511
(0.17)
0.1621
(1.12)
(0.67)
Maximum Drawdown
58.54
76.18
38.64
30.34
15.34
54.02
19.81
27.25
22.1
164.47
Variance
55.59
117.73
29.3
20.13
13.78
58.6
15.47
17.19
16.43
356.59
Market Risk Adjusted Performance
0.7355
(1.21)
1.31
(0.1)
0.018
0.2611
(0.16)
0.1721
(1.11)
(0.66)
Risk Adjusted Performance
0.1371
0.1823
0.0662
(0.0006)
0.0117
0.0546
0.0289
0.0332
0.1249
0.08
Skewness
6.97
4.35
1.26
0.8223
0.6916
4.21
1.59
1.76
1.35
7.22
Semi Deviation
0.0
2.66
4.66
N/A
3.06
4.52
2.88
3.22
2.42
4.26
Information Ratio
0.1644
0.2291
0.0642
(0.03)
(0.02)
0.052
0.0084
0.0152
0.1401
0.092
Value At Risk
(2.70)
(6.06)
(7.08)
(6.47)
(4.36)
(7.81)
(4.94)
(5.45)
(4.51)
(8.08)
Expected Short fall
(2.95)
(7.65)
(4.10)
N/A
(3.39)
(4.56)
(3.22)
(3.21)
(3.39)
(8.49)
Downside Deviation
1.82
3.67
4.86
N/A
3.24
4.93
2.94
3.43
2.9
5.18
Semi Variance
(0.01)
7.1
21.69
N/A
9.38
20.44
8.29
10.34
5.86
18.16

Tourmaline Bio Competition Performance Charts

Five steps to successful analysis of Tourmaline Bio Competition

Tourmaline Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Tourmaline Bio in relation to its competition. Tourmaline Bio's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Tourmaline Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Tourmaline Bio's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Tourmaline Bio, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Tourmaline Bio position

In addition to having Tourmaline Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Health Management Thematic Idea Now

Health Management
Health Management Theme
Major hospitals and healthcare providers. The Health Management theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Consideration for investing in Tourmaline Stock

If you are still planning to invest in Tourmaline Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tourmaline Bio's history and understand the potential risks before investing.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Equity Valuation
Check real value of public entities based on technical and fundamental data
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY